Implications for Practice 1 . Antiretroviral therapy associated mastopathy can clinically present as distressing and socially disturbing mastomegaly. 2. A proper history, laboratory and imaging work-up can establish the diagnosis in most cases. 3. Proper counselling, changing the medicines or reduction mammoplasty is effective in managing such cases.
as females who are human immunodeficiency virus (HIV) infected patients. 1, 2 Important entities that can lead to this mastomegaly are gynaecomastia (proliferation of ducts and periductal stroma), lipomastia (adipose-tissue deposition), and malignancy. We describe a case of a 28-year-old HIVinfected widow, currently on antiretroviral therapy for the past three years and who presented with disturbing bilateral breast enlargement.
Case report
A 28-year-old lady had been receiving antiretroviral therapy for the past three years after being infected from her husband who passed away two years ago. She had no other illnesses. Her family history was unremarkable. Over the past eight months she has been noticing rapid bilateral breast enlargement such that she had to significantly increase the size of her thoracic undergarments (by = /> 4 bra sizes) within this duration. There was neither any history of trauma nor was she lactating. No secretions were being produced or expressed from either of the breasts.
On physical examination both breasts were smooth, firm and freely mobile over the underlying thoracic musculature, and devoid of any palpable mass lesions. There was no nipple discharge, skin abnormalities or any axillary lymphadenopathy ( Figure 1 ). X-ray mammography revealed enlargement of both breasts without any focal obvious mass. Parenchymal opacity was indicative of predominant fatty composition. There were no architectural distortions, abnormal micro calcifications or masses. Overlying skin was neither thickened nor was the nipple puckered ( Figure 2 ). 
Antiretroviral therapy associated mastopathy

No other obvious mass or nodule is seen
Sonomammogram of the breasts showed mastomegaly due to fatty tissue. No obvious mass, nodule or calcification was seen (Figure 3 ). Breast MRI was not performed due to its local unavailability and lack of affordability by the patient.
A final diagnosis of antiretroviral therapy associated mastopathy was thus made based on clinico-radiological findings. The patient was managed by thorough psychological counselling. She was also informed about the option of reduction mammoplasty, which she declined. A written consent was taken from the patient for counselling. 
Discussion
Mastomegaly has been reported in antiretroviral therapyassociated HIV lipodystrophy syndrome in males as well as females. 3 This side effect of multidrug antiretroviral regimes in HIVinfected patients occurs due to changes in fat metabolism and distribution. In this pattern of fat redistribution, on one side there is progressive enlargement of the breast and abdomen while on the other side there is fat loss over the thighs. It is reported in 10% of HIV-infected women treated with combined antiretroviral therapy. 4 Immunology studies showed that in vitro production of TNF alpha and IL-10 was lower and IL-12 production higher in them, though it is not clear whether it is a cause or an effect of fat redistribution. 4 In the same study 50%
of the patients treated with triple therapy had lipodystrophy at one year follow-up, that manifested as weight loss, face-wasting and hyperglycaemia.
Of the multiple antiretroviral drugs available; four protease inhibitors (saquinavir, indinavir, nelfinavir and ritonavir) are associated with the development of abnormal body fat. 5 The pathophysiology for these events remains unclear and a specific drug or drug class linkage is still uncertain.
Following three types of fat distribution have been reported 6 either separately or in combination in HIVinfected patients who are undergoing active antiretroviral therapy:
1. Fat depletion or 'lipoatrophy' syndrome which might be related to the use of stavudine; 2. Mixed syndrome or fat redistribution syndrome related to an unusual side-product of effective virus control; and 3. Subcutaneous adiposity syndrome reflecting increase in caloric intake.
In those who were affected, changing the treatment was associated with limb fat-sparing and fat restoration compared with continued treatment with stavudine and/or protease inhibitor. 7 Treatment options for patients with distress caused by mastomegaly include changing the medicines to halt or regress this lipodystrophy, or sometimes reduction mammoplasty may even be needed. 8 In addition to the medical and surgical aspects, we believe that counselling plays a major role in this scenario. This is because all the different antiretroviral medications may not be available at the same time and cosmetic surgeries are either unaffordable or are not covered under insurance for the common lot. Hence proper explanation may alleviate anxiety in patients so that they come to terms with the new body image and accept the change and prefer not to 'go under the knife', as was seen in the patient reported here. They need to be ensured time and again that this mastomegaly is not a malignancy so that their hopes are sustained and quality of life improved.
